Get started
Author

Keiko Tanimura

Observed names: K. Tanimura, KEIKO TANIMURA, Tanimura Keiko, Tanimura, Keiko, 恵子 谷村, 谷村, 恵子, 谷村恵子
ORCID: 0000-0002-7826-4466
Observed ORCID: 0000-0002-7826-4466
OpenAlex ID: A5043471124
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
2019 · Hirokazu Taniguchi, Tadaaki Yamada, et al. · Nature Communications · 381
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR -Mutated Non–Small Cell Lung Cancer
2020 · Naoko Okura, Naoya Nishioka, et al. · Clinical Cancer Research · 123
Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
2019 · Tadaaki Yamada, Soichi Hirai, et al. · Cancer Medicine · 111
PDF
Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer
2019 · Naoya Nishioka, Junji Uchino, et al. · Journal of Clinical Medicine · 93
PDF
Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients
2020 · Yuki Katayama, Tadaaki Yamada, et al. · Scientific Reports · 39
PDF
Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer
2023 · Hayato Kawachi, Tadaaki Yamada, et al. · JAMA Network Open · 35
PDF
Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
2023 · Yuki Katayama, Tadaaki Yamada, et al. · npj Precision Oncology · 35
PDF
Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management
2018 · Nakano Takayuki, Tanimura Keiko, et al. · BioMed Research International · 35
PDF
High levels of AXL expression in untreated EGFR ‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib
2022 · Akihiro Yoshimura, Tadaaki Yamada, et al. · Cancer Science · 23
PDF
HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features
2022 · Keiko Tanimura, Tadaaki Yamada, et al. · npj Precision Oncology · 23
PDF
TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study
2023 · Yuki Katayama, Tadaaki Yamada, et al. · JTO Clinical and Research Reports · 22
Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer
2019 · Yuki Katayama, Tadaaki Yamada, et al. · Thoracic Cancer · 21
PDF
Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer
2021 · Keiko Tanimura, Tadaaki Yamada, et al. · Cancer Letters · 18
PDF
The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study
2021 · Keiko Tanimura, Tadaaki Yamada, et al. · Frontiers in Oncology · 16
PDF
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study
2023 · Takayuki Takeda, Tadaaki Yamada, et al. · Cancers · 15
PDF
Clinical impact of cancer cachexia on the outcome of patients with non-small cell lung cancer with PD-L1 tumor proportion scores of ≥50% receiving pembrolizumab monotherapy versus immune checkpoint inhibitor with chemotherapy
2024 · Hayato Kawachi, Tadaaki Yamada, et al. · OncoImmunology · 14
Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study
2023 · Keiko Tanimura, Takayuki Takeda, et al. · Cancers · 12
PDF
Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib
2021 · Takayuki Takeda, Tadaaki Yamada, et al. · Diagnostics · 12
PDF
YAP Regulates HER3 Signaling–Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers
2024 · Yuki Katayama, Tadaaki Yamada, et al. · Clinical Cancer Research · 11
Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells
2022 · Yuki Katayama, Tadaaki Yamada, et al. · Cancer Medicine · 11
PDF
Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients
2019 · Tatsuya Imabayashi, Junji Uchino, et al. · Cancers · 11
PDF
Unraveling the influence of TTF-1 expression on immunotherapy outcomes in PD-L1-high non-squamous NSCLC: a retrospective multicenter study
2024 · Naoya Nishioka, Hayato Kawachi, et al. · Frontiers in Immunology · 10
PDF
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non–Small Cell Lung Cancer with PD-L1 Expression Levels of 1% to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study
2024 · Naoya Nishioka, Tae Hata, et al. · Cancer Research and Treatment · 9
PDF
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial
2023 · Keiko Tanimura, Junji Uchino, et al. · The Oncologist · 8
The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer
2019 · Keiko Tanimura, Tadaaki Yamada, et al. · Haigan · 8
PDF
Works count: 115
Citation count: 1,177
H-index: 15
I10-index: 22
Year
Topic
Type